Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R F Tyndale

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Clinical Pharmacology and Therapeutics|May 30, 2013
CYP2A6 genotype but not age determines cotinine half-life in infants and childrenD A Dempsey, N C Sambol, P Jacob, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupationR F Tyndale, S V Bhave, E Hoffmann, et al.
Tobacco Control|November 15, 2002
Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicatorsJ O'Loughlin, J DiFranza, J Tarasuk, et al.
NIDA Research Monograph|January 1, 1996
The documented role of pharmacogenetic: in the identification and administration of new medications for treating drug abuseC V Grudzinskas, R L Woosley, T J Payte, et al.
Tobacco Control|November 27, 2004
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokersJ O'Loughlin, G Paradis, W Kim, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1997
Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in ratsD M Tomkins, S V Otton, N Joharchi, et al.
Clinical Pharmacology and Therapeutics|June 4, 2016
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) CollaborationS W Yee, Y Momozawa, Y Kamatani, et al.
Clinical Pharmacology and Therapeutics|October 29, 2010
Breaking barriers in the genomics and pharmacogenetics of drug addictionM K Ho, D Goldman, A Heinz, et al.
Clinical Pharmacology and Therapeutics|May 25, 2007
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolismJ C Mwenifumbo, C N Lessov-Schlaggar, Q Zhou, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokersM K Ho, J C Mwenifumbo, N Al Koudsi, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Clinical Pharmacology and Therapeutics|May 30, 2013
CYP2A6 genotype but not age determines cotinine half-life in infants and childrenD A Dempsey, N C Sambol, P Jacob, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 23, 1997
Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupationR F Tyndale, S V Bhave, E Hoffmann, et al.
Tobacco Control|November 15, 2002
Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicatorsJ O'Loughlin, J DiFranza, J Tarasuk, et al.
NIDA Research Monograph|January 1, 1996
The documented role of pharmacogenetic: in the identification and administration of new medications for treating drug abuseC V Grudzinskas, R L Woosley, T J Payte, et al.
Tobacco Control|November 27, 2004
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokersJ O'Loughlin, G Paradis, W Kim, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1997
Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in ratsD M Tomkins, S V Otton, N Joharchi, et al.
Clinical Pharmacology and Therapeutics|June 4, 2016
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) CollaborationS W Yee, Y Momozawa, Y Kamatani, et al.
Clinical Pharmacology and Therapeutics|October 29, 2010
Breaking barriers in the genomics and pharmacogenetics of drug addictionM K Ho, D Goldman, A Heinz, et al.
Clinical Pharmacology and Therapeutics|May 25, 2007
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolismJ C Mwenifumbo, C N Lessov-Schlaggar, Q Zhou, et al.
Clinical Pharmacology and Therapeutics|March 13, 2009
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokersM K Ho, J C Mwenifumbo, N Al Koudsi, et al.
Pageof 9